PRESENTATION · Mar 2026 · PDF
Science
Explore conditions, clinical trials, and the latest research.
These pages contain non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
PRESENTATION · Mar 2026 · PDF
BBIO-BBP-418 – MDA 2026 – Additional Data from Phase 3 FORTIFY Interim Analysis
PRESENTATION · Mar 2026 · PDF
BBIO-BBP-418 – MDA 2026 – LGMD2IR9 Health Outcomes Mode
PRESENTATION · Mar 2026 · PDF
BBIO-BBP-418 – MDA 2026 – Journey of BBP-418
PRESENTATION · Mar 2026 · PDF
BBIO-BBP-418 – MDA 2026 – Systematic Literature Review in LGMD2IR9
PRESENTATION · Nov 2025 · PDF
Acoramidis -AHA 2025- Vutisiran HCRU and discontinuation
PRESENTATION · Nov 2025 · PDF
Acoramidis -AHA 2025- D28 sTTR association with CVMCVH
PRESENTATION · Nov 2025 · PDF
Acoramidis -AHA 2025- Atrial fibrillation at baseline and clinical outcomes
PRESENTATION · Nov 2025 · PDF
Acoramidis -AHA 2025- ACM and ACMCVH Subgroup Analysis
PRESENTATION · Nov 2025 · PDF